Biogen Inc. BIIB
What this company does
Written from the business description in BIOGEN INC.'s annual report to the U.S. Securities and Exchange Commission, filed 6 February 2026. Every sentence was checked against that document before publication.
Revenue compounded at −6.0% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 9.9 | 9.7 | 9.8 | 10.2 | 11.0 | 13.4 | 14.4 | 13.5 | 12.3 | 11.4 | 10.8 | 9.7 | 6.9 | 5.5 | 5.0 | 4.7 | 4.4 | 4.1 | 3.2 |
| Operating income $B | 1.6 | 1.9 | 1.3 | · | 2.8 | 4.6 | 7.0 | 5.9 | 5.3 | 5.2 | 4.9 | 4.0 | 2.5 | 1.9 | 1.7 | 1.2 | 1.3 | 1.2 | 0.8 |
| EBITDA $B | 2.3 | 2.6 | 1.8 | · | 3.3 | 5.0 | 7.5 | 6.5 | 6.4 | 5.8 | 5.5 | 4.7 | 3.0 | 2.2 | 2.1 | · | · | · | · |
| Income tax $B | 0.3 | 0.3 | 0.1 | 0.6 | 0.1 | 1.0 | 1.2 | 1.4 | 2.5 | 1.2 | 1.2 | 1.0 | 0.6 | 0.5 | 0.4 | 0.3 | 0.4 | 0.4 | 0.3 |
| Net income $B | 1.3 | 1.6 | 1.2 | 3.0 | 1.6 | 4.0 | 5.9 | 4.4 | 2.5 | 3.7 | 3.5 | 2.9 | 1.9 | 1.4 | 1.2 | 1.0 | 1.0 | 0.8 | 0.6 |
| Free cash flow $B | 2.1 | 2.7 | 1.3 | 1.1 | 3.4 | 3.8 | 6.6 | 5.4 | 3.7 | 4.0 | 3.3 | 2.7 | 2.1 | 1.6 | 1.5 | 1.5 | 0.9 | 1.3 | 0.7 |
| EPS, diluted $ | 8.79 | 11.18 | 7.97 | 20.87 | 10.40 | 24.80 | 31.42 | 21.58 | 11.92 | 16.93 | 15.34 | 12.37 | 7.81 | 5.76 | 5.04 | 3.94 | 3.35 | 2.65 | 1.99 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | · | 11.0 | 8.2 | 25.1 | 14.4 | 33.3 | 44.6 | 34.5 | 20.5 | 34.4 | 35.2 | 30.2 | 23.9 | 20.6 | 20.9 | 17.3 | 16.1 | 13.5 | · |
| Shares out B | 0.15 | 0.15 | 0.14 | 0.14 | 0.15 | 0.15 | 0.17 | 0.20 | 0.21 | 0.22 | 0.22 | 0.23 | 0.24 | 0.24 | 0.24 | 0.24 | 0.00 | 0.29 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
This company against its peers
Reconciled in 19 of 19 fiscal years. 2 checks could not be computed.